Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 47Gastrointestinal 42Head & Neck 11Gynecologic 11Thoracic 10Other hematologic neoplasm 9Tumor-Agnostic 8Genitourinary 6Lymphoid 5Endocrine 3CNS 3Sarcoma 2Plasma cell 1Other solid neoplasm 1Other neoplasm 1Other 1NET 1Dermatologic 1Classical hematology 1

Conditions

Keratosis, Actinic 1Disease 1

Interventions

pembrolizumab 339Nivolumab 305Ipilimumab 274Cyclophosphamide 194aldesleukin 148Interleukin-2 110fludarabine phosphate 106trametinib 85Temozolomide 83Dacarbazine 81fludarabine 80dabrafenib 77Radiotherapy 75Biopsy 75Vemurafenib 71Imiquimod 53Bevacizumab 51sargramostim 50Radiosurgery 49Peripheral Blood Stem Cell Transplantation 49Paclitaxel 49Magnetic Resonance Spectroscopy 49Aminolevulinic Acid 49binimetinib 48Carboplatin 48Specimen Handling 47Blood Specimen Collection 47cemiplimab 46Cisplatin 453-ingenyl angelate 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Control Groups × Dermatologic × Clear all
NCT07335003 2026-01-12

Study of the Photoprotection and Prevention of Actinic Damage With Anthelios Fluide 100 KA+ UVMune 400 in Patients With Multiple Actinic Keratoses

Cosmetique Active International

Phase NA Recruiting
80 enrolled
Dermatologic

Disease, Keratosis, Actinic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡